Avalo Therapeutics Inc (AVTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$6.93-6.98%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Avalo Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.547
Annual ending 2026-12-31
Revenue	—	1M
EPS	—	-2.916
Annual ending 2027-12-31
Revenue	—	1M
EPS	—	-2.978

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into 2029	A supporting condition in Avalo Therapeutics Inc's published investment case. The stated target is Cash reserves to extend into 2029.	Intact	Cash runway projected to fall short of 2029	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management reported cash, cash equivalents and investments increased from $82.0 million at 2026-Q1 to $472.2 million at 2026-Q2, supporting a cash runway expected into 2029. This reflects strong capital discipline and successful financing execution, delivering on the stated priority. Delivery assessment Oct 24, 2026
Initiate Phase 3 trial for abdakibart	They plan to initiate a Phase 3 trial for abdakibart in hidradenitis suppurativa in the first half of 2027.	Intact	Phase 3 trial not initiated by H1 2027	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management announced plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027, following positive Phase 2 LOTUS trial results reported in 2026-Q1. The company is delivering on this priority by progressing clinical development as planned. Delivery assessment Oct 24, 2026
Advance AVTX-010 development	A supporting condition in Avalo Therapeutics Inc's published investment case. The stated target is IND submission for AVTX-010 planned for H1 2027.	Intact	IND submission not made by H1 2027	IND submission planned for H1 2027 vs target H1 2027 CFO sold $1.4m+ stock; analysts cut targets on trial data/financing; no reported IND delay. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management announced the advancement of AVTX-010 with an IND submission planned for the first half of 2027. This represents a strategic pipeline expansion beyond abdakibart. No prior quarters mention this priority, so delivery is at an early stage. Delivery assessment Oct 24, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.98

$-2.76 → $-2.98 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.76	$0	11 / 12
2026-07-25	$-2.76	$0	11 / 12
2026-07-26	$-2.76	$0	11 / 12
2026-07-27	$-2.76	$0	11 / 12
2026-07-28	$-2.76	$0	11 / 12
2026-07-29	$-2.76	$0	11 / 12
2026-07-30	$-2.76	$0	11 / 12
2026-07-31	$-2.76	$0	11 / 12
2026-08-01	$-2.99	$1,000,000	11 / 12
2026-08-02	$-2.76	$0	11 / 12
2026-08-03	$-2.76	$0	11 / 12
2026-08-04	$-2.76	$0	11 / 12
2026-08-05	$-2.76	$0	11 / 12
2026-08-06	$-2.76	$0	11 / 12
2026-08-07	$-3.14	$1,000,000	11 / 12
2026-08-08	$-2.76	$0	11 / 12
2026-08-09	$-2.76	$0	11 / 12
2026-08-10	$-2.76	$0	11 / 12
2026-08-11	$-2.74	$0	11 / 12
2026-08-12	$-2.74	$0	11 / 12
2026-08-13	$-2.63	$0	10 / 13
2026-08-14	$-3.14	$1,000,000	11 / 12
2026-08-15	$-3.14	$1,000,000	11 / 12
2026-08-16	$-3.14	$1,000,000	11 / 12
2026-08-17	$-3.14	$1,000,000	11 / 12
2026-08-18	$-3.14	$1,000,000	11 / 12
2026-08-19	$-3.14	$1,000,000	11 / 12
2026-08-20	$-3.14	$1,000,000	11 / 12
2026-08-21	$-2.88	$1,000,000	11 / 13
2026-08-22	$-2.88	$1,000,000	11 / 13
2026-08-23	$-2.88	$1,000,000	11 / 13
2026-08-24	$-2.88	$1,000,000	11 / 13
2026-08-25	$-2.88	$1,000,000	11 / 13
2026-08-26	$-2.88	$1,000,000	11 / 13
2026-08-27	$-2.88	$1,000,000	11 / 13
2026-08-28	$-2.88	$1,000,000	11 / 13
2026-08-29	$-2.88	$1,000,000	11 / 13
2026-08-30	$-2.88	$1,000,000	11 / 13
2026-08-31	$-2.88	$1,000,000	11 / 13
2026-09-01	$-2.88	$1,000,000	11 / 13
2026-09-02	$-2.88	$1,000,000	11 / 13
2026-09-03	$-2.88	$1,000,000	11 / 13
2026-09-04	$-2.88	$1,000,000	11 / 13
2026-09-05	$-2.88	$1,000,000	10 / 13
2026-09-06	$-2.88	$1,000,000	10 / 13
2026-09-07	$-2.88	$1,000,000	10 / 12
2026-09-08	$-2.88	$1,000,000	10 / 12
2026-09-09	$-2.88	$1,000,000	10 / 12
2026-09-10	$-2.98	$1,000,000	10 / 12
2026-09-11	$-2.98	$1,000,000	10 / 12
2026-09-12	$-2.98	$1,000,000	10 / 12
2026-09-13	$-2.98	$1,000,000	10 / 12
2026-09-14	$-2.98	$1,000,000	10 / 12
2026-09-15	$-2.98	$1,000,000	10 / 12
2026-09-16	$-2.98	$1,000,000	10 / 12
2026-09-17	$-2.98	$1,000,000	10 / 12
2026-09-18	$-2.98	$1,000,000	10 / 12
2026-09-19	$-2.98	$1,000,000	10 / 12
2026-09-20	$-2.98	$1,000,000	10 / 12
2026-09-21	$-2.98	$1,000,000	10 / 12
2026-09-22	$-2.98	$1,000,000	10 / 12
2026-09-23	$-2.98	$1,000,000	10 / 12
2026-09-24	$-2.98	$1,000,000	10 / 12
2026-09-25	$-2.98	$1,000,000	9 / 12
2026-09-26	$-2.98	$1,000,000	9 / 12
2026-09-27	$-2.98	$1,000,000	9 / 12
2026-09-28	$-2.98	$1,000,000	9 / 12
2026-09-29	$-2.98	$1,000,000	9 / 12
2026-09-30	$-2.98	$1,000,000	9 / 12
2026-10-01	$-2.98	$1,000,000	9 / 12
2026-10-02	$-2.98	$1,000,000	9 / 12
2026-10-03	$-2.98	$1,000,000	9 / 12
2026-10-04	$-2.98	$1,000,000	9 / 12
2026-10-05	$-2.98	$1,000,000	9 / 12
2026-10-06	$-2.98	$1,000,000	9 / 12
2026-10-07	$-2.98	$1,000,000	9 / 12
2026-10-08	$-2.98	$1,000,000	9 / 12
2026-10-09	$-2.98	$1,000,000	9 / 12
2026-10-10	$-2.98	$1,000,000	9 / 12
2026-10-11	$-2.98	$1,000,000	9 / 12
2026-10-12	$-2.98	$1,000,000	9 / 12
2026-10-13	$-2.98	$1,000,000	9 / 12
2026-10-14	$-2.98	$1,000,000	9 / 12
2026-10-15	$-2.98	$1,000,000	9 / 12
2026-10-16	$-2.98	$1,000,000	9 / 12
2026-10-17	$-2.98	$1,000,000	9 / 12
2026-10-18	$-2.98	$1,000,000	9 / 12
2026-10-19	$-2.98	$1,000,000	9 / 12
2026-10-20	$-2.98	$1,000,000	9 / 12
2026-10-21	$-2.98	$1,000,000	9 / 12
2026-10-22	$-2.98	$1,000,000	9 / 12
2026-10-23	$-2.98	$1,000,000	9 / 12
2026-10-24	$-2.98	$1,000,000	9 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	0
2026-06-01	14	0
2026-07-01	15	0
2026-08-01	15	0
2026-09-01	15	0
2026-10-01	14	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades2 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BTIGOct 23 · prior May 6

$58.00 → $10.00-82.8%

$0$31.90$63.80

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into 2029Qualitative condition
Initiate Phase 3 trial for abdakibartQualitative condition

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-69.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Avalo Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, where the business case depends on developing medicines rather than established earnings. The long-term thesis is in a watch state: abdakibart is progressing toward a planned Phase 3 program, but recent performance is weak and overall evidence confidence is low.

What's priced into Avalo Therapeutics Inc

The valuation model indicates AVTX trades at a 5.25% premium to peers, with pipeline optionality, or potential future value from development programs, cited as the main reason. Model confidence is low, and the evidence does not specify what investors already assume about clinical success, so the expectations gap is unclear.

What the fundamentals likely do

Near term, results and execution remain uncertain: AVTX had an earnings miss in August, and the next report carries elevated miss risk. Over the multi-year view, management is progressing abdakibart toward a planned Phase 3 start in the first half of 2027 and expects its cash runway to extend into 2029; AVTX-010 is at an earlier stage, with an IND submission planned for the first half of 2027.

What Avalo Therapeutics Inc hinges on

The thesis hinges on advancing abdakibart into Phase 3 and delivering credible progress on AVTX-010, while maintaining enough cash to support development. Near term, weaker guidance or further weak results would add concern; stronger Healthcare-sector earnings could help the sector backdrop, but would not resolve AVTX’s clinical execution risk.